Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Pricing Debate Policy FDA

Drug Importation Working Group Has Been Publicly Invisible As Buzz Grows On Proposal

  • Analysis

Executive Summary

There are rumblings a drug importation proposal is coming, but there are no signs that the HHS/FDA working group has been active in the year since it was created.

You may also be interested in...



Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road

White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.

Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road

White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.

Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means

Did FDA Commissioner Scott Gottlieb and HHS Secretary Alex Azar have a change of heart on importation? Or are they being pressured from above?

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
Pricing Debate Policy FDA
Latest Headlines

Rare Disease Body Wants EU Legislative Overhaul To Address Orphan Definitions & Incentives

‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount

Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation

Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program

See All
UsernamePublicRestriction

Register

PS125593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By